Introduction
The ORMDL proteins and their yeast orthologues, the ORMs, regulate the initiating and rate-limiting enzyme in sphingolipid biosynthesis, serine palmitoyltransferase (SPT) (Breslow et This may not be the case for the mammalian ORMDLs, which lack the sequences that are phosphorylated in the yeast Orms. Clinical interest in ORMDL function has been sparked by the observation that SNPs adjacent to the ORMDL3 gene are highly correlated with risk for childhood asthma (Moffatt et al., 2007; Zhang et al., 2012) . Cookson and colleagues determined that the risk allele correlates with elevated ORMDL3 mRNA expression (Dixon et al., 2007; Moffatt et al., 2007) . It has been suggested that elevated ORMDL3 increases the risk for asthma by depressing sphingolipid biosynthesis (Levy, 2013) . Here we directly test whether ORMDL3 overexpression inhibits de novo sphingolipid biosynthesis in cells derived from one of the tissues important for the asthmatic phenotype, the airway epithelium. We find, surprisingly, that elevated ORMDL3 does not suppress de novo sphingolipid biosynthesis and present evidence that this is because ORMDLs are normally expressed in functional excess relative to SPT. previously described (Siow and Wattenberg, 2012) . Briefly, HeLa and HBEC cells were plated in 12-well plates at various densities depending on the protocol in complete media overnight. The next day, the HeLa cells were transfected as described below and the HBEC stable cells were cultured until desired confluency. Prior to labeling, cells were treated with 10 M C6-ceramide for 60 minutes, where indicated.
Cells were labeled in serine-depleted media (MEM containing 1% dialyzed FBS and 10 Ci/ml 3 Hserine) using 1 ml/well for 60 minutes. Total lipids were extracted by a modification of the Bligh-Dyer extraction (Siow and Wattenberg, 2012 ) and the organic phase was dried under nitrogen. The entire organic phase was then subjected to thin layer chromatography using a solvent system of chloroform:acetic acid:methanol (90:10:2, v/v) and C16-ceramide was spotted in each lane as a standard.
After visualizing the ceramide band by exposure in an iodine tank, the ceramide bands were scraped and incorporated 3 H-serine was measured by liquid scintillation counting.
Measurement of serine palmitoyl transferase activity in permeabilized cells. HBEC cells were plated
into collagen-coated 24-well plates at 0.3x10 6 transfection cells were lifted with trypsin, pelleted, washed with 1X PBS then solubilized for 60 minutes on ice as described above. Solubilized cells were centrifuged at 10,000 rpm x 10 minutes at 4 o C and lysates were moved to clean microfuge tubes. Lysates were then pre-cleared with Protein A beads for 1 hour at 4 o C after which beads were pelleted and discarded and cleared lysates were transferred to clean microfuge tubes. Cleared lysates were incubated on rotator at 4 o C overnight with anti-ORMDL polyclonal antibody (Millipore). Following immunoprecipitation, samples were centrifuged at 10,000 rpm x 10 minutes at 4 o C and supernatants were moved to clean microfuge tubes. Supernatants were incubated with Protein A beads (blocked with 5% BSA in IP buffer) on a rotator @ 4 o C for 2 hours. Beads were then pelleted, post-IP supernatants saved for Western blot analysis and beads were washed 4X with IP buffer containing 0.1% digitonin. 2X Laemmli sample buffer was added to washed beads and they were heated at 60 o C x 30 minutes prior to SDS-PAGE (see Western blot protocol details below).
Overexpression of recombinant ORMDL3 and serine palmitoyltransferase in HeLa cells. Experiments
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Western blot analysis of protein expression levels. Proteins were separated on 12% SDS polyacrylamide gels. Following SDS-PAGE, proteins were transferred to PVDF membrane and membranes were blocked overnight with 5% milk in tris-buffered saline with 0.1% Tween20 (TBST). Blots were cut horizontally using molecular weight markers as a guide depending on the size of proteins to be probed. This allowed blots to be probed with multiple antibodies without the necessity of stripping and reprobing the blots multiple times. Anti-ORMDL (1:2000) and anti-SPTLC1 (1:1000) primary antibodies were incubated overnight at 4 o C in TBST containing 3% milk; anti-beta actin (1:10,000) primary antibody was incubated for 1 hour at room temperature. After incubation with primary antibodies, blots were washed 3X with TBST for 10 minutes per wash. Secondary antibodies (1:20,000) were incubated for 1 hour at room temperature in TBST containing 1% milk. Blots were washed 3X with TBST for 10 minutes per wash.
Protein bands were visualized using ECL Prime solution (GE Life Sciences, Piscataway, NJ) and exposed to film (Denville Scientific, Metuchen, NJ). Densitometry values were measured using Quantity One software and ORMDL3 levels were normalized to beta-actin for each sample. Polybrene® and cells were incubated at 37 o C with 5% CO 2 for 12 hours after which this transduction mix was removed and fresh viral particles were added to the cells for an additional 12 hours. Viral supernatants were removed and complete media was added to cells for overnight incubation. The next day, media was replaced with complete media containing 10 g/mL puromycin to begin the selection process. Cells were maintained under puromycin selection until used for experiments as outlined. Cells were routinely collected and ORMDL3 levels were analyzed by Western blot and real-time PCR.
Subcloning of the lentiviral ORMDL3 construct and generation of human bronchial epithelial cells (HBECs) that stably overexpress
Isolation of total RNA and quantitative real-time PCR analysis.
For each well of cells to be analyzed, 1 mL of TRIzol® was placed directly on the cells. The TRIzol®/cell mixture was transferred to a microfuge tube and stored at -80 o C until analysis. To isolate RNA, the TRIzol®/cell mixture was added to prepared phase lock gels followed by 200 L chloroform:isoamyl alcohol then vigorously shaken for 15 seconds.
Tubes were incubated at room temperature x 5 minutes then centrifuged at 16,000 x g for 15 minutes 
Results
HeLa cells and immortalized, but untransformed, human bronchial epithelial cells express similar
levels of the three ORMDL isoforms and serine palmitoyltransferase subunit 1.
Airway epithelial cells are thought to be a major cell type involved in the increased asthma risk resulting from the elevated expression of ORMDL3 induced by a risk allele in ORMDL3-adjacent sequences (Miller et al., 2012) . Here we utilize a well characterized cell line derived by immortalization of primary human airway cells by expression of telomerase (hTERT) and cyclin-dependent kinase 4 (Cdk) (Ramirez et al., 2004) . We refer to these as HBEC (Human Bronchial Epithelial Cells). To enable comparison of ORMDL function between HBEC and the more easily manipulated HeLa cell line we measured mRNA levels of the three ORMDL isoforms and one of the two major catalytic subunits of serine palmitoyltransferase (SPT), SPTLC-1 (Figure 1 ). We found that levels of these transcripts were at comparable levels when each transcript is compared between these two cell lines. Additionally we measured levels of these transcripts in the lung adenocarcinoma cell line A549 and found comparable levels of all transcripts in that cell line as well. Levels of these transcripts may differ among other cell lines and may change during cell differentiation (Kiefer et al., 2014) . In experiments outlined below we study the role of stochiometry in ORMDL/SPT regulation. The expression data illustrated in Figure 1 suggests that the relative stoichiometry of these proteins is similar between these cell lines. present in functional excess relative to SPT. To test this we overexpressed, in HeLa cells, a construct that results in the expression of a single polypeptide that is a fusion of the two major catalytic subunits of SPT (SPTLC-1 and -2) and a small subunit that enhances SPT activity (ssSPTa) (SPTLC2-ssSPTa-SPTLC-1) (Gable et al., 2010) ( Figure 3 ). The predicted size of this construct is 129KDa. We observe a triplet of bands close to this molecular weight when immunoblots are probed with an antibody directed against SPTLC-1. The origin of the multiple bands is not clear. We term this construct single-chain SPT (scSPT).
Overexpression of ORMDL3 does not suppress
Expression of scSPT results in an approximately 5-fold increase in de novo ceramide biosynthesis ( Figure   3 , panels A and B). We do not detect any change in ORMDL protein or RNA resulting from this overexpression (Figure 3 , Panels C and D, note that this antibody detects all three ORMDL isoforms).
Depletion of all three ORMDL isoforms by siRNA transfection strongly enhances ceramide biosynthesis at both endogenous levels of SPT and at the elevated levels of synthesis resulting from the scSPT expression ( Figure 3 (Figure 3, panel B ). As before, at endogenous SPT levels, ORMDL3 overexpression did not inhibit sphingolipid synthesis, in fact in the experiment depicted in Figure 3 sphingolipid synthesis was slightly elevated. However, strikingly, ORMDL3 expression significantly inhibited de novo ceramide synthesis in scSPT expressing cells and enhanced the C6-ceramide inhibition of ceramide synthesis in those cells. This strongly supports the notion that SPT/ORMDL stoichiometry determines whether SPT activity is regulated by levels of ORMDL expression.
Mass spectroscopic analysis was performed on HeLa cell cultures overexpressing either the single-chain SPT, ORMDL3, or both to examine whether the effects on de novo sphingolipid synthesis, depicted in 
SPT/ORMDL complex formation is not enhanced by ORMDL overexpression. The measurement of
de novo sphingolipid biosynthesis depicted in Figure 3 indicated that ORMDLs are in functional excess relative to SPT at endogenous levels. To establish whether this is reflected by the formation of stable SPT/ORMDL complexes we examined the levels of these complexes by co-immunoprecipitation of SPT with anti-ORMDL antibodies. Overexpressed ORMDL has been shown to form a complex with SPT (Breslow et al., 2010) . We confirmed that this interaction takes place at endogenous levels of these proteins ( Figure 5 ). Specificity of this precipitation was confirmed by performing immunoprecipitations using lysates prepared from cells depleted of ORMDL proteins by siRNA transfection (Figure 5 ). To assess whether increased expression of ORMDL3 might elevate SPT/ORMDL complex formation, we compared the level of SPT immunoprecipitated by anti-ORMDL antibodies at endogenous levels of ORMDLs to that when ORMDL3 levels were elevated by overexpression ( Figure 5 ). Note that for the overexpression shown in Panel A we utilized an epitope-tagged version of human ORMDL3 that migrates somewhat slower in SDS-polyacrylamide gels than the native protein. We find that this epitope-tagged version is as efficient as the untagged mouse ORMDL3 in functional assays such as that depicted in Figure 3 and supports the notion that ORMDLs are in excess relative to SPT. We also examined whether the efficiency of ORMDL/SPT complex formation was affected under conditions which trigger ORMDL inhibition of SPT. Cells were treated with C6-ceramide, which strongly depresses de novo sphingolipid synthesis ((Siow and Wattenberg, 2012), (Figure 3 ) and lysates were then prepared and subjected to immunoprecipitation with an anti-ORMDL antibody. We were unable to detect any change in the level of SPT co-precipitation with ORMDL when cells were pretreated with C6-ceramide. This result indicates that ORMDL inhibition is not a product of increased ORMDL/SPT association, but rather a change in the nature of that association within the complex.
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Low-level ORMDL3 overexpression in airway epithelial cells results in slightly reduced mass levels of sphingolipids. We have established that overexpression of ORMDL3 slightly does not inhibit sphingolipid biosynthesis in airway epithelial cells (Figure 2 .) Considering the complexity of sphingolipid metabolism it was important to establish how ORMDL3 overexpression impacted steady state levels of these lipids. Sphingolipids were extracted from vector control HBEC and two HBEC cell lines expressing ORMDL3 at either moderate or highly elevated levels and lipids were analyzed by mass spectroscopy (Figure 6 ). ORMDL3 overexpression slightly depressed levels of all sphingolipid species measured, but only reached statistical significance in the HBEC cells expressing slightly elevated ORMDL3 ("Low"). This trend was also observed in the HBEC cells expressing higher ORMDL3 levels ("High"), but the differences were not statistically significant. Levels of sphingosine-1-phosphate and dihydrosphingosine-1-phosphate were below the levels of detection in this analysis. The distribution of individual ceramide molecular species did not differ between samples (Data not shown) except for C16dihydroceramide, which was slightly, but significantly, reduced in the ORMDL3-Low and ORMDL3-High cell lines.
Discussion
These studies were designed to examine the concept that increased ORMDL3 expression elevates asthma risk by depressing sphingolipid biosynthesis, as suggested by earlier publications (Levy, 2013; Worgall et al., 2013) . Our results present a complex picture. We clearly find that increased ORMDL3 levels do not suppress sphingolipid synthesis, as previously assumed, at least in the cell types that we have examined.
The lack of suppression of sphingolipid biosynthesis by elevated ORMDL3 expression is a consequence of the fact that in the two cell types studied there is sufficient ORMDL, at normal levels, to maximally form stable ORMDL/SPT complexes. Only when we artificially elevate SPT levels do we see that increased ORMDL expression inhibits de novo sphingolipid biosynthesis. These results mirror those of two publications that emerged while this manuscript was in revision, which reported that elevating ORMDL levels had no effect on sphingolipid biosynthesis and steady state levels in Hek293 cells (Kiefer of the three isoforms is therefore unresolved. Vicente and colleagues find that overexpression of all three isoforms has no effect on sphingolipid synthesis under normal conditions, but report that when cells are supplemented with palmitate, the coenzyme-A form of which is one of the substrates for SPT, they can distinguish an effect of co-expression of all three ORMDL isoforms from expression of any single isoform (Kiefer et al., 2014) . The significance of this finding will require further investigation of the ORMDL/SPT complex and its regulation.
Our results, and those inferred from results in yeast (Breslow et al., 2010) indicate that the level of ORMDL regulation of SPT is not a result of the level of ORMDL expression and ORMDL/SPT complex formation, but rather that ORMDLs exist in both non-inhibitory and inhibitory states in stable ORMDL/SPT complexes. In yeast, Orm inhibitory activity is constitutive, but is relieved by phosphorylation of the Orms (Breslow et al., 2010; Roelants et al., 2011) . However the mammalian ORMDLs, although otherwise highly homologous to the yeast proteins, lack the amino terminal sequences that are phosphorylated in the Orms (Breslow et al., 2010) . Further, we have been unable to detect ORMDL phosphorylation under any conditions (data not shown.) Therefore the mechanism that triggers ORMDL inhibitory activity in response to elevated cellular sphingolipid levels remains a mystery. We have previously shown that the sphingolipid that activates the ORMDL-dependent homeostatic inhibition of SPT is ceramide or a higher order sphingolipid such as sphingomyelin or glycosphingolipid (Siow and Wattenberg, 2012) . These lipids may be sensed by an as yet unidentified protein that interacts with the ORMDL/SPT complex. Alternately, the ORMDLs may directly sense sphingolipid levels.
Other cell types relevant to the asthmatic phenotype, such as smooth muscle or immune cells, may have intrinsically lower levels of ORMDLs relative to SPT and therefore elevation of ORMDL3 would have a inhibitory effect, such as that we see with enforced SPT expression. Careful examination of these cell types will be required to establish whether this is the case. However it does not appear that this simple explanation for ORMDL3-mediated effects on asthma risk holds for the airway epithelium. Instead our data indicates that ORMDL3 has additional cellular roles that should be examined. Our finding that It is important to recognize that although the association of elevated asthma risk with SNPs that raise ORMDL3 levels is strong and reproducible, the increase in risk is moderate and the prevalence of the risk alleles of these SNPs is very high (Zhang et al., 2012) . This indicates that there are important environmental and genetic factors that interact with ORMDL3 elevation to increase asthma risk. The challenge will be to unravel the contribution that ORMDL3 makes to increasing the risk for this prevalent disease. expressing lines. Cell monolayers were incubated for 60 minutes in the presence ("+C6") or absence ("NT") of 10 M C6-ceramide after which they were labeled for 60 minutes with 3 H-serine and incorporation of 3 H-serine into ceramide was determined as described in Methods. HeLa cells were transiently transfected with either empty vector or mouse ORMDL3 (not epitope tagged) for 24 hours prior to treatment with 10 M C6-ceramide after which they were labeled for 60 minutes with 3 H-serine Immunoprecipitates and lysates were immunoblotted for ORMDL (below line) and SPTLC1(above line) as described in Methods. by guest, on October 30, 2017
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